Intravenous itraconazole emulsions produced by SolEmuls technology

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 56, Issue 1, 2003, Pages 29-36

  Akkar, Aslihan ^a   Müller, Rainer H ^a,b  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

^b Pharmasol GmbH   (Germany)

Author keywords

Emulsions; High pressure homogenisation; Itraconazole; Particle size; Poorly soluble drugs; SolEmuls

Indexed keywords

ITRACONAZOLE; NANOPARTICLE; PHOSPHATIDYLCHOLINE;

ARTICLE; DRUG DISTRIBUTION; DRUG SOLUBILITY; DRUG SOLUTION; DRUG STABILITY; EMULSION; PARTICLE SIZE; ROOM TEMPERATURE; TEMPERATURE SENSITIVITY;

EID: 0038692100     PISSN: 09396411     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0939-6411(03)00063-8     Document Type: Article

References (25)

1. A. Akkar, R.H. Müller, Drug nanocrystals produced by high pressure homogenisation, access of therapeutics to the brain, Eighth UKICRS Symposium, Belfast 10 January, Abstract Book, Poster No. 12, 2003.
2. Merisko-Liversidge E., Sarpotdar P., Bruno J., et al. Formulation and antitumor activity evaluation of nanocrystalline suspensions of poorly soluble anticancer drugs. Pharm. Res. 13:(2):1996;272-278.
3. R.H. Müller, R. Becker, B. Kruss, K. Peters, Pharmaceutical nanosuspensions for medicament administration as systems with increased saturation solubility and rate of dissolution, United States Patent No. 5, 858 410 (1999).
4. R.H. Müller, K. Mäder, K. Krause, Method for controlled production of ultra-fine microparticles and nanoparticles, PCT Application PCT/EP00/06535, 2000.
5. Krause K.P., Kayser O., Mäder K., Gust R., Müller R.H. Heavy metal contamination of nanosuspensions produced by high pressure homogenisation. Int. J. Pharm. 196:2000;169-172.
6. S. Buchmann, W. Fischli, F.P. Thiel, R. Alex, Mainz, Proceedings of the Annual Congress of the International Association for Pharmaceutical Technology (APV), 1994, 124 pp.
7. M.R. Hilborn, Abstracts of 'Particles 2002' 20-23 April, Orlando, Florida, Abstract no. 48, 2002, p. 50.
8. G. Vergnault, Workshop 'Nanobiotech medicine' Nanobiotech 2001, Münster, 2001, pp. 24-27.
9. Bruno R.P., Mcllwrick R. Microfluidizer processor technology for high performance particle size reduction, mixing and dispersion. Müller R.H., Böhm B.H.L. Dispersion Techniques for Laboratory and Industrial Scale Processing. 2001;77-86 Wissenschaftliche Verlagsgesellschaft mbH, Stuttgart.
10. Sucker H. Hydrosole, eine Alternative für die Parenterale Anwendung von schwer wasser löslichen Wirkstoffen. Müller R.H., Hildebrand G.E. Pharmazeutische Technologie: Moderne Arzneiformen. second ed. 1997;383-391 Wissenschaftliche Verlagsgesellschaft mbH, Stuttgart.
11. Peters K., Leitzke S., Diederichs J.E., Borner K., Hahn H., Müller R.H., Ehlers S. Preparation of Clofazimin nanosuspension for intravenous use and evaluation of its therapeutic efficiency in murine Mycobacterium avium infection. J. Antimicrob. Chemother. 45:(1):2000;77-83.
12. R.H. Müller, M. Lück, J. Kreuter, DE 19745950 A1 (1997), United States Int. J. Pharm. Patent 6, 288, 040 (2001).
13. Geβner A., Olbrich C., Schröder W., Kayser O., Müller R.H. The role of plasma proteins in brain targeting: species dependent protein absorption patterns on brain-specific lipid drug conjugate (LDC) nanoparticles. Int. J. Pharm. 214:2001;87-91.
14. J.E. Kipp, Using NANOEDGE in the rapid development of water-insoluble drug formulations, Conference Documentation of the Seventh Annual Drug Delivery Partnerships Conference/Institute for International Research (IIR), January 28-30, San Diego, vol. B4 (Workshop 1), 2003.
15. S.S. Davis, C. Washington, Drug emulsion, European Patent 0296845B1 (1988).
16. R.H. Müller, Dispersions for the formulation of slightly or poorly soluble agents, DE 100 36 871.9 (2000), PCT application PCT/EP01/08726 (2001).
17. Akkar A., Müller R.H. SolEmuls for poorly soluble drugs: physical background of novel formulation principle. Arch. Pharm. Pharm. Med. Chem. 335:(Suppl. 1):2002;56.
18. R.H. Müller, Zetapotential und Partikelladung in der Laborpraxis, APV Paperback Nr. 37, Wissenschaftliche Verlagsgesellschaft mbH, Stuttgart, 1996, p. 179.
19. Müller R.H., Heinemann S. Fat emulsions for parenteral nutrition. I: evaluation of microscopic and laser light scattering methods for the determination of the physical stability. Clin. Nutr. 11:1992;223-236.
20. Verwey E.J.W., Overbeek J.T.G. Theory of the Stability of Lyophobic Colloids. 1948;Elsevier, Amsterdam.
21. Düzgünes N., Wilshut J., Fraley R., Papahadjopoulos D. Studies on the mechanism of membrane fusion. Role of head-group composition in calcium- and magnesium-induced fusion of mixed phospholipid vesicles. Biochim. Biophys. Acta. 642:1981;182-195.
22. R.H. Müller, S. Schmidt, I. Buttle, A. Akkar, J. Schmitt, S. Brömer, SolEmuls technology for the formulation of i.v. emulsions with poorly soluble drugs, Pharm. Res., submitted for publication.
23. List P.H. Arzneiformenlehre, Wissenschaftliche. 1982;Verlagsgesellschaft GmbH, Stuttgart.
24. Müller R.H., Böhm B.H.L. Nanosuspensions. Müller R.H., Benita S., Böhm B.H.L. Emulsions and Nanosuspensions for the Formulation of Poorly Soluble Drugs. 1998;153 Medpharm Scientific Publishers, Stuttgart.
25. A. Akkar, Poorly soluble drugs: formulation by nanocrystals and SolEmuls® technologies, PhD thesis, Department of Pharmaceutical Technology, Biotechnology and Quality Management, Free University of Berlin, submitted.